Antiviral prodrugs and nanoformulations thereof
Nanoformulations of cabotegravir prodrugs with aliphatic modifications provide sustained drug release and improved biodistribution, addressing limitations of current LAPs by maintaining effective plasma concentrations and reducing injection site reactions, thus enhancing HIV treatment adherence and efficacy.
Patent Information
- Authority / Receiving Office
- AU · AU
- Patent Type
- Applications
- Current Assignee / Owner
- BOARD OF RGT UNIV OF NEBRASKA
- Filing Date
- 2024-08-22
- Publication Date
- 2026-07-16
AI Technical Summary
Current long-acting antiretroviral (LAP) formulations of cabotegravir (CAB) face challenges such as intolerable injection site reactions, limited dosing intervals, and variable drug absorption, necessitating improvements in formulation to enhance regimen adherence and maintain effective plasma concentrations.
Development of prodrugs of integrase inhibitors, such as cabotegravir, modified with aliphatic or alkyl groups, encapsulated in nanoparticles with amphiphilic block copolymers, to create stable nanoformulations that provide sustained drug release and improved biodistribution.
The nanoformulations achieve prolonged plasma half-life and tissue retention of cabotegravir, maintaining therapeutic levels for up to a year with reduced injection volumes and adverse reactions, enhancing treatment adherence and efficacy against HIV.
Smart Images
Figure 00000065_0000 
Figure 00000065_0001 
Figure 00000065_0002